Alumis — Third Quarter 2026 Earnings Summary

Alumis Inc. reported a net loss of $94.9 million for the third quarter of 2026, driven by $80.8 million in research and development expenses and $20.2 million in general and administrative costs. The company highlighted new Phase 3 data for its lead candidate envudeucitinib in plaque psoriasis, which demonstrated rapid and durable improvements in skin clearance and itch resolution, supporting a planned New Drug Application submission in the fourth quarter of 2026. Conversely, the Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus did not meet its primary endpoints in the overall population, though robust responses were observed in a subgroup with high interferon gene signatures. As of September 30, 2026, Alumis held $431.3 million in cash and marketable securities, which is expected to fund operations through the fourth quarter of 2027.